Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA

BACKGROUND AND OBJECTIVES: Durvalumab and atezolizumab are approved as first-line therapy in extensive-stage small-cell lung cancer. Although cost-effectiveness analyses compared these immunotherapy drugs with standard chemotherapy-alone regimens, no head-to-head cost-effectiveness comparisons for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ionova, Yelena, Vuong, Wilson, Sandoval, Omar, Fong, Jodie, Vu, Vincent, Zhong, Lixian, Wilson, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188525/
https://www.ncbi.nlm.nih.gov/pubmed/35604530
http://dx.doi.org/10.1007/s40261-022-01157-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188525/
https://www.ncbi.nlm.nih.gov/pubmed/35604530
http://dx.doi.org/10.1007/s40261-022-01157-3

Ejemplares similares